BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

University of Texas MD Anderson Cancer Center Acquires Second Aushon Biosystems' 2470 Microarray Printer for its RPPA Core Facility


7/27/2011 8:53:35 AM

BILLERICA, Mass.--(BUSINESS WIRE)--Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis announced today that the Department of Systems Biology at the MD Anderson Cancer Center has acquired another 2470 microarray printer from Aushon BioSystems. The new 2470 Arrayer will be utilized in the Cancer Center Support Grant (CCSG) Functional Proteomics Reverse Phase Protein Array (RPPA) Facility, a core facility that serves all researchers at MD Anderson Cancer Center, as well as other academic institutions and industries. Extremely high demand for RPPA data and the proven performance of the existing 2470 Arrayer helped drive the acquisition of the additional microarray printer. Combined with the current 2470 on-site, the ability of the Functional Proteomics RPPA Facility to meet the higher throughput demands for biomarker research and diagnostic testing on cancer patients’ protein pathways and drug reaction will be significantly expanded.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->